Chronic Urticaria Or Hives - Pipeline Review, H1 2018

  • ID: 4529322
  • Report
  • 65 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • ELORAC Inc
  • F. Hoffmann-La Roche Ltd
  • Faes Farma SA
  • Fountain Biopharma Inc
  • Genentech Inc
  • GlaxoSmithKline Plc
  • MORE
Chronic Urticaria Or Hives - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Chronic Urticaria Or Hives - Pipeline Review, H1 2018, provides an overview of the Chronic Urticaria Or Hives (Dermatology) pipeline landscape.

Chronic urticaria also known as hives, are an outbreak of swollen, pale red bumps, patches, or welts on the skin that appear suddenly either as a result of allergies, or for other reasons. The main symptom is itchy rashes. Chronic urticaria occurs when histamine and other chemicals are released from under the skin's surface, causing the tissues to swell. Predisposing factors include stress, caffeine, warm temperatures, alcohol and insect bites and stings. Treatment includes antihistamines and corticosteroids.

Report Highlights:

This latest pipeline guide Chronic Urticaria Or Hives - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Chronic Urticaria Or Hives (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Urticaria Or Hives (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Urticaria Or Hives and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 4, 5, 4 and 4 respectively.

Chronic Urticaria Or Hives (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Urticaria Or Hives (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Chronic Urticaria Or Hives (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chronic Urticaria Or Hives (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chronic Urticaria Or Hives (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Urticaria Or Hives (Dermatology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chronic Urticaria Or Hives (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chronic Urticaria Or Hives (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • ELORAC Inc
  • F. Hoffmann-La Roche Ltd
  • Faes Farma SA
  • Fountain Biopharma Inc
  • Genentech Inc
  • GlaxoSmithKline Plc
  • MORE
Introduction

Report Coverage

Chronic Urticaria Or Hives - Overview

Chronic Urticaria Or Hives - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Chronic Urticaria Or Hives - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Chronic Urticaria Or Hives - Companies Involved in Therapeutics Development

ELORAC Inc

F. Hoffmann-La Roche Ltd

Faes Farma SA

Fountain Biopharma Inc

Genentech Inc

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

Mycenax Biotech Inc

Novartis AG

Synermore Biologics Co Ltd

Chronic Urticaria Or Hives - Drug Profiles

AK-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bilastine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cetirizine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cidoxepin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GDC-0853 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2646264 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ligelizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LOU-064 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mepolizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omalizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omalizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chronic Urticaria Or Hives - Dormant Projects

Chronic Urticaria Or Hives - Discontinued Products

Chronic Urticaria Or Hives - Product Development Milestones

Featured News & Press Releases

Mar 06, 2018: Novartis' Xolair recommended in new global chronic urticaria guideline

Sep 16, 2017: Novartis Xolair confirms re-treatment efficacy in chronic spontaneous urticaria patients after treatment interruption

Jun 20, 2017: Novartis real world study shows almost half of chronic urticaria patients are not receiving any treatment despite significant disease burden

Jun 19, 2017: Xolair added to seven Canadian public drug plans to treat chronic idiopathic urticaria (hives)

Mar 24, 2017: Anti-IgE antibody formulation "Zolare" acquired additional indication as a treatment for idiopathic chronic urticaria

Dec 19, 2016: Aralez Announces Commercial Launch Of BLEXTEN In Canada

Nov 18, 2016: Taiho and Meiji Announce the Launch of Bilanoa Tablets 20 mg, an Oral Anti-allergy Drug in Japan

Sep 28, 2016: Taiho Pharmaceutical Receives Approval to Manufacture and Market Bilanoa Tablets, an Oral Anti-allergy Drug in Japan

Apr 25, 2016: Aralez Receives Health Canada Approval For BLEXTEN

Nov 13, 2015: Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market TAC-202 (bilastine), an Oral Anti-allergy Drug in Japan

Jun 12, 2015: Novartis reports new analysis showing Xolair improving quality of life by 78% for chronic spontaneous urticaria patients

May 25, 2015: Bilastine in Japan: Phase III trials completed and ready for registration

Aug 28, 2014: Novartis announces that Xolair is approved in Canada as a licensed therapy for chronic idiopathic urticaria (CIU) patients unresponsive to antihistamines

May 07, 2014: FDA Approves Xolair for Treatment of Chronic Hives

Mar 21, 2014: Novartis announces US FDA approval of Xolair for chronic idiopathic urticaria

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Table 1: Number of Products under Development for Chronic Urticaria Or Hives, H1 2018

Table 2: Number of Products under Development by Companies, H1 2018

Table 3: Products under Development by Companies, H1 2018

Table 4: Number of Products by Stage and Target, H1 2018

Table 5: Number of Products by Stage and Mechanism of Action, H1 2018

Table 6: Number of Products by Stage and Route of Administration, H1 2018

Table 7: Number of Products by Stage and Molecule Type, H1 2018

Table 8: Chronic Urticaria Or Hives - Pipeline by ELORAC Inc, H1 2018

Table 9: Chronic Urticaria Or Hives - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Table 10: Chronic Urticaria Or Hives - Pipeline by Faes Farma SA, H1 2018

Table 11: Chronic Urticaria Or Hives - Pipeline by Fountain Biopharma Inc, H1 2018

Table 12: Chronic Urticaria Or Hives - Pipeline by Genentech Inc, H1 2018

Table 13: Chronic Urticaria Or Hives - Pipeline by GlaxoSmithKline Plc, H1 2018

Table 14: Chronic Urticaria Or Hives - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2018

Table 15: Chronic Urticaria Or Hives - Pipeline by Mycenax Biotech Inc, H1 2018

Table 16: Chronic Urticaria Or Hives - Pipeline by Novartis AG, H1 2018

Table 17: Chronic Urticaria Or Hives - Pipeline by Synermore Biologics Co Ltd, H1 2018

Table 18: Chronic Urticaria Or Hives - Dormant Projects, H1 2018

Table 19: Chronic Urticaria Or Hives - Discontinued Products, H1 2018

List of Figures

Figure 1: Number of Products under Development for Chronic Urticaria Or Hives, H1 2018

Figure 2: Number of Products under Development by Companies, H1 2018

Figure 3: Number of Products by Targets, H1 2018

Figure 4: Number of Products by Stage and Targets, H1 2018

Figure 5: Number of Products by Mechanism of Actions, H1 2018

Figure 6: Number of Products by Stage and Mechanism of Actions, H1 2018

Figure 7: Number of Products by Routes of Administration, H1 2018

Figure 8: Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Figure 9: Number of Products by Molecule Types, H1 2018

Figure 10: Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • ELORAC Inc
  • F. Hoffmann-La Roche Ltd
  • Faes Farma SA
  • Fountain Biopharma Inc
  • Genentech Inc
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd
  • Mycenax Biotech Inc
  • Novartis AG
  • Synermore Biologics Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll